Cargando…

Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis

The aims of the present study are to describe the characteristics of rheumatoid arthritis (RA) patients selected for tocilizumab (TCZ), compare the “real-world” effectiveness of TCZ and tumour necrosis factor inhibitors (TNFi) when used as a first biologic and assess the influence of past biologic e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kihara, Mari, Davies, Rebecca, Kearsley-Fleet, Lianne, Watson, Kath D., Lunt, Mark, Symmons, Deborah P.M., Hyrich, Kimme L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer London 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290047/ https://www.ncbi.nlm.nih.gov/pubmed/27913894 http://dx.doi.org/10.1007/s10067-016-3485-5

Ejemplares similares

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2016)

Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register
por: Verstappen, Suzanne M. M., et al.
Publicado: (2010)

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti‑TNF therapy: results from the British Society for Rheumatology Biologics Register
por: Davies, Rebecca, et al.
Publicado: (2011)

Long-term persistence with rituximab in patients with rheumatoid arthritis
por: Oldroyd, Alexander G S, et al.
Publicado: (2018)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register
por: Fagerli, Karen Minde, et al.
Publicado: (2018)

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2011)

Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register
por: Fagerli, Karen M, et al.
Publicado: (2019)

The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register
por: Mercer, Louise K, et al.
Publicado: (2012)

Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Mercer, Louise K, et al.
Publicado: (2017)

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2018)

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Mercer, Louise K, et al.
Publicado: (2015)

Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register
por: McErlane, Flora, et al.
Publicado: (2013)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
por: Davies, Rebecca, et al.
Publicado: (2015)

Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
por: Saad, Amr A, et al.
Publicado: (2009)

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register
por: Galloway, J B, et al.
Publicado: (2011)

Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register
por: Dixon, W G, et al.
Publicado: (2010)

Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
por: Hyrich, Kimme L., et al.
Publicado: (2009)

Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2016)

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
por: Saad, Amr A., et al.
Publicado: (2010)

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
por: Saad, Amr A., et al.
Publicado: (2017)

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
por: Galloway, James B., et al.
Publicado: (2011)

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
por: Dixon, W G, et al.
Publicado: (2009)

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register
por: Lord, Paul A. C., et al.
Publicado: (2010)

Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity
por: Pan, Yi, et al.
Publicado: (2019)

Correction: Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity
por: Pan, Yi, et al.
Publicado: (2020)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register
por: Dixon, W G, et al.
Publicado: (2007)

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
por: Hyrich, Kimme L., et al.
Publicado: (2011)

Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register
por: Verstappen, Suzanne M M, et al.
Publicado: (2011)

Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register
por: Dixon, W G, et al.
Publicado: (2010)

Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis
por: Taylor, Thomas R.P., et al.
Publicado: (2021)

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
por: Low, Audrey S. L., et al.
Publicado: (2016)

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
por: Galloway, James B, et al.
Publicado: (2013)

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register
por: Harrison, M J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_gdv76mr4ffe85l1pd02cglv31v